Suppr超能文献

普萘洛尔的受体结合是人体血浆浓度动力学与效应时程之间缺失的环节。

Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.

作者信息

Wellstein A, Palm D, Pitschner H F, Belz G G

出版信息

Eur J Clin Pharmacol. 1985;29(2):131-47. doi: 10.1007/BF00547412.

Abstract

In a double-blind, placebo-controlled study in 6 healthy volunteers, the correlation between beta-adrenoceptor binding, the time course of the effect and plasma concentration kinetics was investigated from 0 to 48 h after a single oral dose of propranolol 240 mg. First, the in vitro beta-adrenoceptor interaction of propranolol was investigated. Propranolol inhibited beta-adrenoceptor binding to rat parotid (beta 1) and reticulocyte (beta 2) membranes in the presence of pooled human plasma with a Ki of about 8 ng/ml plasma. After oral administration of 240 mg propranolol, concentration kinetics in plasma could be described by a Bateman function with a fictive concentration at time 0 of 275 ng/ml plasma, and a mean elimination half-life of 3.5 h. Using the concentration kinetics of propranolol in plasma together with its in vitro beta-adrenoceptor binding characteristics in the presence of placebo plasma from each individual, the time course of antagonism against beta-adrenoceptor mediated effects was predicted. The latter was in agreement with the time course of propranolol-induced inhibition of tachycardia due to orthostasis. After bicycle ergometry, however, the time course of inhibition of tachycardia was shorter than was predicted. Plasma sampled at various times after propranolol administration inhibited beta-adrenoceptor binding of the radioligand 3H-CGP 12177 to rat reticulocyte membranes in a fashion reflecting the time course of inhibition of exercise tachycardia observed in the volunteers. A direct, linear relation was shown between the in vitro inhibition of beta-adrenoceptor binding by the plasma samples withdrawn after propranolol administration and the inhibition of exercise tachycardia observed in parallel. The results show that the concentrations of antagonist present in plasma are representative of the concentrations in the effect compartment. Deep compartments of drug distribution appear irrelevant to the effects of the drugs. The relation between the plasma concentration of propranolol and the reduction in heart rate at various levels of physical effort shows no significant inhibition at rest and increasing IC50-values from orthostasis to 2 min and to 4 min of ergometry. IC50-values after orthostasis are in the range of the Ki-values from in vitro receptor binding studies, whereas the IC50-values after exercise are shifted 2- to 3-fold to the right relative to the Ki-values. This finding is in agreement with increased beta-adrenoceptor stimulation with increasing effort (release of endogenous noradrenaline), which shifts the antagonist concentration-effect curve to the right.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

在一项针对6名健康志愿者的双盲、安慰剂对照研究中,研究了单次口服240 mg普萘洛尔后0至48小时内β-肾上腺素能受体结合、效应时程与血浆浓度动力学之间的相关性。首先,研究了普萘洛尔的体外β-肾上腺素能受体相互作用。在合并的人血浆存在下,普萘洛尔抑制β-肾上腺素能受体与大鼠腮腺(β1)和网织红细胞(β2)膜的结合,其Ki约为8 ng/ml血浆。口服240 mg普萘洛尔后,血浆浓度动力学可用贝特曼函数描述,0时的虚拟浓度为275 ng/ml血浆,平均消除半衰期为3.5小时。利用普萘洛尔在血浆中的浓度动力学及其在每个个体的安慰剂血浆存在下的体外β-肾上腺素能受体结合特性,预测了对β-肾上腺素能受体介导效应的拮抗时程。后者与普萘洛尔诱导的因直立性低血压导致的心动过速抑制时程一致。然而,在自行车测力计运动后,心动过速抑制的时程比预测的要短。普萘洛尔给药后不同时间采集的血浆以反映志愿者中观察到的运动性心动过速抑制时程的方式抑制放射性配体3H-CGP 12177与大鼠网织红细胞膜的β-肾上腺素能受体结合。普萘洛尔给药后采集的血浆样本对β-肾上腺素能受体结合的体外抑制与同时观察到的运动性心动过速抑制之间呈现直接的线性关系。结果表明,血浆中存在的拮抗剂浓度代表效应室中的浓度。药物分布的深部室似乎与药物效应无关。普萘洛尔血浆浓度与不同体力水平下心率降低之间的关系显示,静息时无明显抑制,从直立性低血压到测力计运动2分钟和4分钟时IC50值增加。直立性低血压后的IC50值在体外受体结合研究的Ki值范围内,而运动后的IC50值相对于Ki值向右移动2至3倍。这一发现与随着运动强度增加(内源性去甲肾上腺素释放)β-肾上腺素能受体刺激增加一致,这会使拮抗剂浓度-效应曲线向右移动。(摘要截选至400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验